0001607854-15-000001.txt : 20150211
0001607854-15-000001.hdr.sgml : 20150211
20150211141937
ACCESSION NUMBER: 0001607854-15-000001
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20150211
DATE AS OF CHANGE: 20150211
EFFECTIVENESS DATE: 20150211
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: Lysosomal Therapeutics, Inc.
CENTRAL INDEX KEY: 0001607854
IRS NUMBER: 454015802
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-233905
FILM NUMBER: 15598808
BUSINESS ADDRESS:
STREET 1: 21 BLACKSTONE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-913-0166
MAIL ADDRESS:
STREET 1: 21 BLACKSTONE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
D
1
primary_doc.xml
X0707
D
LIVE
0001607854
Lysosomal Therapeutics, Inc.
19 BLACKSTONE STREET
CAMBRIDGE
MA
MASSACHUSETTS
02139
617-714-9620
DELAWARE
None
None
Corporation
true
2011
Cornelis
Been
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Executive Officer
Director
Carole
Neuchterlein
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Director
Clay
Thorp
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Director
Daniel
Geffken
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Executive Officer
Robert
Carpenter
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Director
Bruce
Booth
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Director
Bernard
Davitian
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Director
Steven
Hall
c/o Lysosomal Therapeutics, Inc.
19 Blackstone Street
Cambridge
MA
MASSACHUSETTS
02139
Director
Biotechnology
Decline to Disclose
- 06b
false
2015-01-30
false
true
false
0
20000004
10000002
10000002
false
9
0
0
0
false
Lysosomal Therapeutics, Inc.
/s/ Cornelis Been
Cornelis Been
President & CEO
2015-02-05